BAL30072 is a novel siderophore (iron-binding) sulfactam antibiotic conferring potent bactericidal activity against Gram-negative pathogens.
NDM-1 is an enzyme that leads to resistance towards antibiotics that have been the mainstay of treatment of clinically important pathogens such as Escherichia coli or Klebsiella pneumoniae.
BAL30072 phase I clinical testing in-vitro data presented at ECCMID/ICC has shown that it is resistant to degradation by NDM-1 and is active against many of the highly resistant isolates tested while standard anti-Gram-negative antibiotics such as meropenem, ceftazidime or aztreonam covered only a minority of the strains.
BAL30072 and meropenem, when combined, enhanced activity and resulted in inhibition of more than 90% of the isolates.
BAL30072 was tested alongside reference drugs currently used for the treatment of Acinetobacter infections and showed greater activity than all the marketed beta-lactam antibiotics as well as most of the other comparators.